کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3933545 1253353 2010 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
Incidence of thrombophilia and venous thrombosis in transsexuals under cross-sex hormone therapy
چکیده انگلیسی

ObjectiveTo evaluate the incidence of venous thromboembolism (VTE) in transsexual patients and the value of screening for thrombophilia in this population.DesignRetrospective cohort study.SettingAcademic research institution.Patient(s)Two hundred fifty-one transsexuals (162 male-to-female [MtF] and 89 female-to-male [FtM] transsexuals).Intervention(s)Screening for activated protein C (aPC) resistance, antithrombin III, free protein S antigen, and protein C deficiency.Main Outcome Measure(s)Incidence of thrombophilic defects and VTE during cross-sex hormone therapy.Result(s)Activated protein C resistance was detected in 18/251 patients (7.2%), and protein C deficiency was detected in one patient (0.4%). None of the patients developed VTE under cross-sex hormone therapy during a mean of 64.2 ± 38.0 months. There was no difference in the incidence of thrombophilia comparing MtF and FtM transsexuals (8.0% [13/162] vs. 5.6% [5/89], respectively).Conclusion(s)VTE during cross-sex hormone therapy is rare. General screening for thrombophilic defects in transsexual patients is not recommended. Cross-sex hormone therapy is feasible in MtF as well as in FtM patients with aPC resistance.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Fertility and Sterility - Volume 93, Issue 4, 1 March 2010, Pages 1267–1272
نویسندگان
, , , , ,